Top Page
Kangji Medical Holdings Limited
(9997)
Kangji Medical Holdings Limited (9997) vs. iShares MSCI Hong Kong ETF (EWH)
Kangji Medical Holdings Limited Business Overview & Revenue Model
Kangji Medical Holdings Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.05B | 1.01B | 926.02M | 786.37M | 690.26M | 511.49M |
| Gross Profit | 826.89M | 797.65M | 741.20M | 635.25M | 562.93M | 431.47M |
| EBITDA | 617.76M | 562.61M | 464.58M | 586.65M | 427.25M | 319.14M |
| Net Income | 561.35M | 581.44M | 504.02M | 478.74M | 456.79M | 250.30M |
Balance Sheet | ||||||
| Total Assets | 3.06B | 2.92B | 4.26B | 3.98B | 3.39B | 3.02B |
| Cash, Cash Equivalents and Short-Term Investments | 1.77B | 1.24B | 2.69B | 2.83B | 3.01B | 2.78B |
| Total Debt | 921.00K | 3.52M | 43.99M | 49.02M | 4.05M | 5.05M |
| Total Liabilities | 461.50M | 289.39M | 319.97M | 266.10M | 129.94M | 83.65M |
| Stockholders Equity | 2.59B | 2.63B | 3.65B | 3.37B | 3.26B | 2.94B |
Cash Flow | ||||||
| Free Cash Flow | 485.41M | 504.52M | 331.70M | 243.62M | 404.88M | 203.21M |
| Operating Cash Flow | 537.60M | 560.10M | 419.62M | 319.31M | 435.75M | 221.04M |
| Investing Cash Flow | -239.21M | 1.04B | -391.70M | -369.98M | -160.09M | -610.98M |
| Financing Cash Flow | -1.66B | -1.70B | -243.53M | -472.79M | -97.61M | 2.15B |
Kangji Medical Holdings Limited Technical Analysis
Kangji Medical Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | €10.63B | 17.45 | 23.40% | 2.90% | 6.51% | 4.85% | |
| ― | €2.16B | 14.04 | 3.76% | 6.67% | 21.39% | -0.57% | |
| ― | HK$5.32B | 25.72 | 10.31% | 1.00% | 14.06% | 3.02% | |
| ― | HK$25.46B | 12.08 | 8.34% | 4.29% | 0.74% | 2.13% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Kangji Medical Holdings Limited Corporate Events
Kangji Medical Holdings Limited is undergoing a privatization process proposed by Knight Bidco Limited through a scheme of arrangement under the Companies Act. The scheme document has been dispatched to shareholders, and the Independent Board Committee, along with the Independent Financial Adviser, has recommended that shareholders vote in favor of the proposal, deeming it fair and reasonable.
The most recent analyst rating on (HK:9997) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Kangji Medical Holdings Limited stock, see the HK:9997 Stock Forecast page.
Kangji Medical Holdings Limited has announced a court-directed meeting for its independent shareholders to consider and potentially approve a scheme of arrangement. This meeting, scheduled for November 10, 2025, in Hong Kong, is a significant step in the company’s strategic planning, potentially impacting its operational structure and shareholder relations.
The most recent analyst rating on (HK:9997) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Kangji Medical Holdings Limited stock, see the HK:9997 Stock Forecast page.
Kangji Medical Holdings Limited has announced an Extraordinary General Meeting (EGM) scheduled for November 10, 2025, to discuss and potentially approve a Scheme of Arrangement. This involves a capital reduction and subsequent issuance of shares to Knight Bidco Limited, as well as a potential withdrawal of the company’s shares from the Stock Exchange. The meeting will also address a Special Deal under the Takeovers Code, which requires shareholder approval. These actions could significantly impact the company’s share structure and market presence.
The most recent analyst rating on (HK:9997) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Kangji Medical Holdings Limited stock, see the HK:9997 Stock Forecast page.
Kangji Medical Holdings Limited has announced an update on its privatization proposal by Knight Bidco Limited through a scheme of arrangement. The company is in the process of finalizing the Scheme Document, with a court hearing scheduled for October 6, 2025. The proposal’s implementation is contingent on fulfilling certain conditions, including court approval. Additionally, the company clarified that Bin Yuan Capital Limited and LYFE Capital Management Limited are not current shareholders.
The most recent analyst rating on (HK:9997) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Kangji Medical Holdings Limited stock, see the HK:9997 Stock Forecast page.
Kangji Medical Holdings Limited and Knight Bidco Limited have announced the satisfaction of all pre-conditions for the proposed privatization of Kangji Medical by way of a scheme of arrangement. This development marks a significant step towards the company’s delisting, pending further conditions such as court approval, which could impact its market presence and shareholder arrangements.
The most recent analyst rating on (HK:9997) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Kangji Medical Holdings Limited stock, see the HK:9997 Stock Forecast page.
Kangji Medical Holdings Limited has announced a delay in the dispatch of its Scheme Document related to its proposed privatization by Knight Bidco Limited through a scheme of arrangement. The delay is due to the need for additional time to fulfill pre-conditions, finalize the Scheme Document, and obtain directions from the Grand Court, which is currently on vacation. The extension has been approved, and the document is now expected to be dispatched by October 31, 2025. This delay may impact the timeline for the company’s privatization and subsequent withdrawal of its listing, potentially affecting stakeholders’ plans and expectations.
The most recent analyst rating on (HK:9997) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Kangji Medical Holdings Limited stock, see the HK:9997 Stock Forecast page.
Kangji Medical Holdings Limited reported an 8.3% increase in revenue for the first half of 2025, reaching RMB496.6 million, driven by higher sales of disposable products. However, the company’s net profit attributable to owners decreased by 7.0% due to reduced other income and gains, and increased losses from its associate, Weijing Medical. The Board did not recommend an interim dividend for this period.
The most recent analyst rating on (HK:9997) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Kangji Medical Holdings Limited stock, see the HK:9997 Stock Forecast page.
Kangji Medical Holdings Limited has announced the appointment of Somerley Capital Limited as the Independent Financial Adviser to guide the Independent Board Committee regarding the fairness and reasonableness of a proposed privatization scheme. This move is part of a broader strategy involving a scheme of arrangement under the Companies Act, with the aim of privatizing the company. The proposal’s implementation is contingent upon certain conditions being met, and stakeholders are advised to exercise caution.
The most recent analyst rating on (HK:9997) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Kangji Medical Holdings Limited stock, see the HK:9997 Stock Forecast page.
Kangji Medical Holdings Limited has announced a board meeting scheduled for August 28, 2025, to discuss and approve the interim results for the first half of the year and consider an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and potential returns for stakeholders.
Kangji Medical Holdings Limited has announced a pre-conditional proposal for its privatization by Knight Bidco Limited through a scheme of arrangement under the Companies Act. This proposal includes the withdrawal of its listing from the Stock Exchange, with shareholders receiving HK$9.25 per share, representing a significant premium over recent trading prices. The completion of this scheme will result in Kangji Medical becoming a wholly-owned subsidiary of Knight Bidco Limited, impacting its market presence and shareholder structure.